Lottie : Gleevec & leukemia news

[Guest guest]

Lottie

Thanks for all the news -

Just a note to let you know that everyone always appreciates the

effort you go to for all of us to be more informed.

Thanks for the skin info - sounds like you may have had me in mind.

I have had nearly all the skin reactions in a variety of ways and

not all at the same time - that was advertised in the Mayo News.

Keep well and thanks for sharing

Love to Jimmy

Sue (Aussie)

>

> Some of this information is current as of a few days ago, so you

may want to print it or file it for future use.

> I know most of us who have been or are still on Gleevec usually

look to the Novartis site, but I found this site from Mayo Clinic

that is more in depth.

> Serious skin reactions can occur during treatment with this

medicine. Check with your doctor right away if you have any of the

following symptoms while taking this medicine: blistering, peeling,

loosening of skin, chills, cough, diarrhea, fever, itching, joint or

muscle pain, red skin lesions, sore throat, sores, ulcers, white

spots in mouth or on lips, or unusual tiredness or weakness .

www.mayoclinic.com/health/drug-information/DR601855

> ------------------------------------------------------------------

> New research shows that Gleevec, a cancer drug used to treat

chronic myelogenous leukemia (CML) and certain types of stomach

tumors, also has potential as a treatment for autoimmune diseases

such as rheumatoid arthritis. Stanford University researchers

published their findings online Sept. 14 issue of the Journal of

Clinical Investigation. The study will be published in the October

print edition of the journal.

http://www.healthcentral.com/rheumatoid-arthritis/c/38/2334/drug-ra/

> ----------------------------------------------------------------

> In this study, Grant and colleagues examined the effects of

combining MK-0457 with vorinostat, a novel targeted agent that has

recently been approved for the treatment of cutaneous T-cell

lymphoma. They found that this combination leads to a dramatic

induction of apoptosis, or programmed cell death in CML cells,

including imatinib-resistant cells bearing the T315I or other

mutations. The article was pre-published as a First Edition Paper in

Blood, the journal of the American Society of Hematology, which

appeared online May 27.

> This work was supported by grants from the National Institutes of

Health, the Leukemia and Lymphoma Society of America, the V

Foundation, and the Department of Defense. Merck Pharmaceuticals

supplied the agents tested in the preclinical studies.

http://www.medicalnewstoday.com/articles/109347.php

> -------------------------------------------------------------------

--------

> What if a way could be found to reprogram cancerous cells back

into normal cells? A team of Syracuse University researchers

believes it may have found a way to do just that. Led by

Cosgrove, assistant professor of biology in SU's College of Arts and

Sciences, the team discovered a way to disrupt the protein switch

that is a critical component in the process to create white blood

cells. Its discoveries could lead to a more effective way to treat

some forms of leukemia and revolutionize the approach to treating

other forms of cancer. The research was recently published online in

the prestigious Journal of Biological Chemistry of the American

Society for Biochemistry and Molecular Biology, and is forthcoming

in the print edition. " We believe our discovery is just the tip of

the iceberg, " Cosgrove says. " Our hope is that from the knowledge we

have gained in understanding how these proteins work in normal

cells, we will be able to find new ways to treat all types of

leukemia. We also think the discoveries will have broad implications

in treating other types of cancer. " All of the cells in the body

begin as stem cells with the same DNA.

> Cosgrove earned a Ph.D. at Syracuse University and was a

postdoctoral researcher at the s Hopkins School of Medicine and

Cornell University.

> http://www.medicalnewstoday.com/articles/127301.php

> ----------------------------------------------------------

> OCTOBER 28, 2008 ARIAD's second oncology product candidate,

AP24534, is an investigational oral multi-targeted tyrosine kinase

inhibitor that has broad potential applications in cancer. In

preclinical studies, AP24534 has demonstrated potent inhibition of

kinase targets associated with drug-resistant chronic myeloid

leukemia and acute myeloid leukemia, as well as proliferation and

angiogenesis in multiple solid tumors. In addition to an ongoing

Phase 1 clinical study in hematological malignancies, further

clinical development in patients with solid tumors is expected to

begin in 2009. Additional information about the ongoing clinical

trial can be found at

http://clinicaltrials.gov/ct2/show/NCT00660920?term=AP24534 & rank=1.

> FYI,

> Lottie

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>